Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, announced that it has entered into a multi-target multi-modality strategic research collaboration and license agreement with Eli Lilly and Company (“Lilly”). Stipple Bio will leverage its innovative Pointillist Platform and extensive research experience to discover novel tumor-specific cell surface epitope binders, which Lilly will combine with its proprietary oncology technologies to advance high therapeutic index compounds across multiple modalities.
Under the terms of the agreement, Stipple Bio will receive an upfront payment and an equity investment from Lilly. Lilly receives exclusive worldwide rights to develop and commercialize products arising from the collaboration. Stipple Bio will be eligible to receive aggregate payments of up to $5.9 billion upon achievement of research, product development and commercialization milestones, as well as tiered royalties on product sales should Lilly successfully commercialize therapies from the collaboration.
WilmerHale advised Stipple Bio in the collaboration and license agreement.
The WilmerHale team was led by Judith Hasko and included Mike Sweeney, Eugena Liu, Bruce Manheim Jr., and Fred Adam.